Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Gutierrez

Pain Medicine San Ramon, CA Medical Doctor

NPI 1518961127 CMS profile 341386

100 Park Pl 120, Suite 120, San Ramon, CA 94583

Open in the dashboard

General payments

$2,392

40 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Gutierrez of San Ramon, CA is reported in the CMS Open Payments database as having received $2,392 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,452 10
2024 General $54 3
2023 General $70 3
2022 General $69 5
2021 General $53 4
2020 General $581 9
2019 General $113 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Gutierrez
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Susan Gutierrez were reported at $1,452. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Susan Gutierrez Pain Medicine median Middle half National median
2019 $113 $506 $144–$1,566 $163
2020 $581 $315 $96–$934 $114
2021 $53 $452 $134–$1,237 $132
2022 $69 $475 $124–$1,407 $149
2023 $70 $480 $136–$1,384 $160
2024 $54 $521 $164–$1,511 $164
2025 $1,452 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $1,416 8 payments
  2. Stimwave Technologies Incorporated $529 7 payments
  3. Abbott Laboratories $156 9 payments
  4. Allergan Inc. $57 3 payments
  5. SPR Therapeutics, Inc $53 3 payments
  6. Medtronic USA, Inc. $34 2 payments
  7. Biodelivery Sciences International, Inc. $28 2 payments
  8. Nevro Corp. $27 1 payment
  9. Avanos Medical $24 1 payment
  10. Nalu Medical, Inc. $21 1 payment
  11. Other $50 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,564 6 payments
  2. Food and Beverage $828 34 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,416 8 payments
  2. SCS FreedonSpinal Cord Stimulator $509 5 payments
  3. CFNS StimQ Peripheral Nerve StimulatorSystem $488 4 payments
  4. PROCLAIM $126 7 payments
  5. BOTOX $57 3 payments
  6. SPRINT PNS System $53 3 payments
  7. MYSTIM $34 2 payments
  8. BELBUCA $28 2 payments
  9. Senza $27 1 payment
  10. COOLIEF* COOLED RADIOFREQUENCY $24 1 payment
  11. Other $200 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

577

Median for Interventional Pain Management: 1,220

Drug cost

$40,500

Median for Interventional Pain Management: $39,344

Branded share of claims

32.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 43 $30,326
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 75 $2,656
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 59 $2,154
Lidocaine Generic 23 $1,300
Gabapentin Generic 130 $1,072
Oxycodone Hcl Generic 23 $795
Duloxetine Hcl Generic 57 $593
Pregabalin Generic 13 $294
Cyclobenzaprine Hcl Generic 25 $265
Bupropion Xl Bupropion Hcl Brand 12 $247

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$173,278

Medicare's payments for the services billed

Medicare patients

208

Average age 74

Services billed

1,617

140 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 37%
Diabetes 30%
Ischemic heart disease 26%
Osteoporosis 24%
Chronic kidney disease 19%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record